Dr. Peter Andrews discusses what the term “pluripotency” means in relation to ES and iPS cells, how the term has evolved, and how to assess pluripotent potential by comparing existing assays. Dr. Andrews is co-director of the Centre for Stem Cell Biology at the University of Sheffield. This presentation and the following Q&A session were moderated by Dr. Ludovic Vallier from the Wellcome Trust Sanger Institute.
This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
Note: Some original data from this presentation has been omitted to abide by copyright rules.
To view the webinar, please complete the form, or sign in to your account.